Unlocking the Potential of APBA3: A Potential Drug Target for the Treatment of Alzheimer's Disease

Target Name: APBA3

NCBI ID: G9546

APBA3

Unlocking the Potential of APBA3: A Potential Drug Target for the Treatment of Alzheimer's Disease

Alzheimer's disease is a debilitating and progressive neurological disorder that affects millions of people worldwide. It is characterized by the accumulation of neurofibrillary tangles and senile plaques in the brain, leading to the progressive loss of memory, thinking, and behavior. Currently, there is no cure for Alzheimer's disease, and the only available treatment is supportive care, which aims to alleviate the symptoms and improve the quality of life of the patients.

The search for new treatments and biomarkers for Alzheimer's disease has led to the exploration of various protein structures and their involvement in the disease. One of these proteins is APBA3, a member of the family A of the X11-like 2 protein family.

APBA3: A Potential Drug Target

The APBA3 protein is a 120-kDa protein that is expressed in various tissues and cells, including brain, heart, and skeletal muscles. It is highly conserved and has a similar structure to other proteins in the X11-like 2 family, which includes several key proteins, including APB2, APB3, and APB4.

The functions of APBA3 and its related proteins have not yet been fully understood, but they are involved in various cellular processes, including cell signaling, protein synthesis, and stress response. One of the most promising aspects of APBA3 is its potential as a drug target.

Drugs that Target APBA3

Several drugs that target APBA3 have been developed and are in various stages of clinical trials. These drugs include:

1. AC-1458: This is an oral small molecule that binds to APBA3 and inhibits its activity. It has been shown to improve memory and cognitive function in animal models of Alzheimer's disease.

2. BAY 94-9340: This is an oral small molecule that binds to APBA3 and inhibits its activity. It has been shown to reduce the formation of neurofibrillary tangles and improve memory and cognitive function in animal models of Alzheimer's disease.

3. IDH1- targeted therapy: This is a form of cancer treatment that uses antibodies to target and destroy IDH1, a gene that is mutated in many types of cancer, including Alzheimer's disease.

4. Small interfering RNA (siRNA) therapy: This is a form of gene therapy that uses small interfering RNAs (siRNAs) to target and destroy specific genes that are involved in the development and progression of Alzheimer's disease.

Conclusion

The discovery of APBA3 as a potential drug target for Alzheimer's disease has significant implications for the treatment of this debilitating and progressive disorder. Further research is needed to fully understand the functions of APBA3 and its potential as a drug target. If approved, these drugs have the potential to improve the quality of life for people with Alzheimer's disease and provide a new treatment option for this devastating disease.

Protein Name: Amyloid Beta Precursor Protein Binding Family A Member 3

Functions: May modulate processing of the amyloid-beta precursor protein (APP) and hence formation of APP-beta. May enhance the activity of HIF1A in macrophages by inhibiting the activity of HIF1AN

The "APBA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APBA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets